The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
 
Andreas Nicholas Saltos
Research Funding - Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Prime Oncology
 
Tawee Tanvetyanon
No Relationships to Disclose
 
Ben C. Creelan
Consulting or Advisory Role - Abbvie; ARMO BioSciences; AstraZeneca/MedImmune; BerGenBio; Boehringer Ingelheim; E.R. Squibb Sons, LLC; Gilead Sciences; GlaxoSmithKline; KSQ Therapeutics
Speakers' Bureau - ARIAD; AstraZeneca/MedImmune; Foundation Medicine; Genentech/Roche; Takeda
Research Funding - Biodesix (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); NeoGenomics Laboratories (Inst); Prometheus (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Michael Rahman Shafique
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Amphivena (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck Serono (Inst); Nektar (Inst); PsiOxus Therapeutics (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Janssen Research & Development; Nektar; Vaccinex
 
Scott Joseph Antonia
Stock and Other Ownership Interests - Cellular Biomedicine Group
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cellular Biomedicine Group; Memgen; Merck; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; FLX Bio; Memgen; Merck; Novartis
 
Eric B. Haura
Consulting or Advisory Role - Janssen Oncology
Research Funding - AstraZeneca (Inst); FORMA Therapeutics; Genentech (Inst); Incyte; Janssen (Inst); Novartis (Inst); Revolution Medicines (Inst)
Patents, Royalties, Other Intellectual Property - Protein-Protein Interactions as Biomarkers Patent
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; Roche
 
Hong Zheng
Employment - Bristol-Myers Squibb (I)
 
Margaret Barlow
No Relationships to Disclose
 
James Saller
No Relationships to Disclose
 
Anna Castellano-Fornelli
Stock and Other Ownership Interests - Merck
 
Antoine Richards
No Relationships to Disclose
 
Ram Thapa
No Relationships to Disclose
 
Theresa A. Boyle
Travel, Accommodations, Expenses - Illumina
 
Dung-Tsa Chen
Research Funding - Abbvie (Inst)
 
Amer A Beg
Stock and Other Ownership Interests - Amarin Corporation; Cellectar; Endocyte; Navidea
Consulting or Advisory Role - Memgen; Vividion Therapeutics
Patents, Royalties, Other Intellectual Property - Gene signature for the prediction of NF-kappaB activity Patent number: 9115388; ONCOLYTIC VIRUS OR ANTIGEN PRESENTING CELL MEDIATED CANCER THERAPY USING TYPE I INTERFERON AND CD40-LIGAND (Pending patent)
Travel, Accommodations, Expenses - Vividion Therapeutics
 
Jhanelle Elaine Gray
Honoraria - AstraZeneca; Axiom Healthcare Strategies; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Lilly; Merck; Takeda
Consulting or Advisory Role - AstraZeneca; Axiom Healthcare Strategies; Axiom Healthcare Strategies; Bristol-Myers Squibb; Celgene; EMD Serono; EMD Serono; Merck; Merck; Novartis; Takeda
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Serono; Novartis; Takeda